Abstract
Introduction
The clinical benefit of anticoagulant treatment for various indications is offset by the risk of bleeding. The impact of bleeding related to vitamin K antagonist (VKA) use, in terms of patients' discomfort or temporary disability and in terms of both medical and socio-economic resources is not negligible1-4. However, the majority of studies have focused on major bleeding, used obsolete definitions of bleeding and have not distinguished between clinically relevant non-major bleeding (CRNMB) and minor events2,3. The International Society on Thrombosis and Haemostasis provided a standard definition of CRNMB in 2015 as those events that are not major but require any kind of medical intervention. [...]
Downloads
PDF
- Abstract viewed - 310 times
- PDF downloaded - 84 times